At Work With: Charlene Prounis

Charlene Prounis
Charlene Prounis
CHARLENE PROUNIS
CEO and managing partner, Flashpoint Medica

What was your biggest break?

Landing the Herceptin account without a pitch. We got the business based on the project work we did, which the client loved. Life without a pitch—a dream fulfilled!

What is the best and worst part of your job?

Best part—the energy of new business pitches, expanding into new categories, doing research, strategizing and coming up with positioning. Worst part: reconciliations.

Where did you go to college? Did it help prepare you for your career?

I started out as nurse, getting my BSN from Adelphi, and running an ICU in my early 20's. Then I got an MBA from St. John's University at night while working in advertising. Every step prepared me for the challenges I face today.

What books are you currently reading?

I'm reading Lean In (about women's advancement), Power of Habit (our job, after all is about breaking habits) and The Happiness Project (who doesn't want to be happier?). I also love novels.

What was your greatest professional challenge?

Transforming the agency to be fully digitally integrated. Now we are a digital agency.




You must be a registered member of MMM to post a comment.
close

Next Article in Careers

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.